Company Overview
About Tune Therapeutics
Tune Therapeutics is an epigenome editing company that silences disease-causing genes without making permanent DNA cuts — a potentially safer approach than traditional gene editing for chronic diseases. The company raised $175 million in Series B financing led by Hevolution Foundation (the world's largest longevity-focused philanthropic fund), NEA, and Regeneron Ventures, and has dosed its first patient in Phase 1/2 clinical trials for Tune-401, targeting chronic hepatitis B.
Business Model & Competitive Advantage
Chronic hepatitis B (CHB) affects 296 million people globally and is not curable with existing antivirals because HBV DNA integrates into the human genome and forms covalently closed circular DNA (cccDNA) that persists indefinitely. Tune-401 simultaneously silences both integrated HBV DNA and episomal cccDNA using epigenetic writers that methylate viral promoters without cutting DNA — the first approach capable of targeting both reservoirs simultaneously.
Competitive Landscape 2025–2026
Tune's TEMPO platform can theoretically be applied to any disease where gene silencing (rather than permanent knockout) is the therapeutic objective — including oncology, inflammatory disease, and neurological conditions. The Regeneron Ventures participation provides strategic access to Regeneron's protein engineering capabilities and potential co-development agreements for combination therapies that pair TEMPO silencing with Regeneron's monoclonal antibodies.
Open Positions
Reddit Discussions
Key Differentiators
Emerging Innovator
Tune Therapeutics is an emerging player bringing innovative solutions to the BioTech market.
Growth Stage
Tune Therapeutics has achieved $175M in revenue, demonstrating strong product-market fit.
Frequently Asked Questions
Not So Random Others
a2z Radiology AI
a2z Radiology AI has developed a whole-body CT analysis platform that simultaneously screens for over 24 medical conditions across a single CT scan, including incidental cancers, coronary artery disea
Adept AI
Adept AI was founded in 2022 by a team of former OpenAI, DeepMind, and Google Brain researchers to build AI that can take actions on computers — navigating software interfaces, filling forms, and exec
Duckie
Duckie is a San Francisco-based AI customer support platform — backed by Y Combinator (W24) with $500,000 in funding from Y Combinator, Andreessen Horowitz, Greylock, KungHo Fund, Netflix, and 5 addit
Plenty
Plenty is a San Francisco-based indoor vertical farming company that uses AI, machine learning, and robotics to grow leafy greens and other produce in controlled indoor environments. The company has r
Oura
Oura is the maker of the Oura Ring, a premium smart ring that tracks sleep, recovery, readiness, and health metrics through continuous biometric sensing. The company raised $900 million in Series E fi
Nira Energy
Nira Energy is a Denver-based renewable energy software company providing grid capacity mapping and interconnection analysis tools that help solar, battery storage, and data center developers identify
Compare Tune Therapeutics with Competitors
Side-by-side AI visibility scores, platform breakdown, and market position.
Claim This Profile
Are you from Tune Therapeutics? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.
Claim Tune Therapeutics Profile →Track AI Visibility in Real Time
Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Tune Therapeutics vs competitors. Get alerts when AI recommendations shift.
Start Free Tracking →